Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.34 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448114 | 0.86 | P2RX7 (0.38) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27401568 | 0.84 | IDO1 (0.40) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7574925 | 0.82 | HTR3E (0.43) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL16593769 | 0.80 | P2RX7 (0.35) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28005085 | 0.80 | IDO1 (0.38) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27895332 | 0.80 | KIF11 (0.41) | IDO1P2RX7GLAPOLBGAA | |
| SCHEMBL8624138 | 0.78 | IDO1 (0.37) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18935992 | 0.78 | P2RX7 (0.38) | IDO1NOTUMP2RX7GLAPOLB | |
| SCHEMBL8321579 | 0.78 | IDO1 (0.37) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1026527 | 0.78 | CSNK2A2 (0.39) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102863342-A | Preparation method of high-purity 2, 6-dichloro-4-trifluoromethyl aniline | HUBEI MASTEAM BIO TECHNOLOGY CO LTD | 2013-01-09 | — | — | CN | claimed |
| EP-0330137-B1 | Intermediate compounds for the preparation of 1,2,4-triazolo [1,5-a]pyrimidine-2-sulfonamides | DOWELANCO (US) | 1994-03-02 | — | — | EP | claimed |
| EP-0330137-A1 | Intermediate compounds for the preparation of 1,2,4-triazolo [1,5-a]pyrimidine-2-sulfonamides | DowElanco (US) | 1989-08-30 | — | — | EP | claimed |
| EP-0142152-A2 | Novel substituted 1,2,4-triazolo- [1,5-a] pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil | THE DOW CHEMICAL COMPANY (US) | 1985-05-22 | — | — | EP | claimed |
| US-12344571-B1 | Organic color center-tailored, semiconducting carbon nanotubes and their method of manufacture | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2025-07-01 | — | — | US | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8410082-B2 | Fluorinated diaryl urea derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| CN-102863342-A | Preparation method of high-purity 2, 6-dichloro-4-trifluoromethyl aniline | HUBEI MASTEAM BIO TECHNOLOGY CO LTD | 2013-01-09 | — | — | CN | disclosed |
| EP-1140785-B1 | METHOD FOR PREPARING POLYHALOGENATED PARATRIFLUOROMETHYLANILINES | BASF AGRO B V ARNHEM NL WAEDEN (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6479703-B1 | Method for preparing polyhalogenated paratrifluoromethylanilines | AVENTIS CROPSCIENCE SA (FR) | 2002-11-12 | — | — | US | disclosed |
| EP-1140785-A1 | METHOD FOR PREPARING POLYHALOGENATED PARATRIFLUOROMETHYLANILINES | AVENTIS CROPSCIENCE S.A. (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035851-A1 | METHOD FOR PREPARING POLYHALOGENATED PARATRIFLUOROMETHYLANILINES | AVENTIS CROPSCIENCE S.A. (FR) | 2000-06-22 | — | — | WO | disclosed |
| EP-0330137-B1 | Intermediate compounds for the preparation of 1,2,4-triazolo [1,5-a]pyrimidine-2-sulfonamides | DOWELANCO (US) | 1994-03-02 | — | — | EP | disclosed |
| US-4954163-A | PRE-AND POSTEMERGENCE HERBICIDES | THE DOW CHEMICAL COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| US-4886883-A | HERBICIDES | THE DOW CHEMICAL COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| US-4818273-A | Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides | THE DOW CHEMICAL COMPANY (US) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | IDO1 3445/4885HTR3E 4013/4885HTR3B 3624/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | IDO1 3445/4885HTR3E 4013/4885HTR3B 3624/4885 |
| US-12344571-B1 | Organic color center-tailored, semiconducting carbon nanotubes and their method of manufacture | NOS1, NOS3, NOS2 | IDO1 268/4885HTR3E 4359/4885HTR3B 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.